The new drug would allow patients to produce the needed clotting protein for an extended period, reducing the need for constant intravenous infusions or injections, which are painful as well as inconvenient.

Pfizer's Hympavzi receives FDA approval as the first anti-TFPI therapy for hemophilia A and B. This subcutaneous, once-weekly treatment reduces bleeding rates and offers convenience via an auto-injector pen.

The FDA approved Pfizer’s Hympavzi, which can be an alternative to intravenous infusions often administered multiple times a week.

The U.S. Food and Drug Administration approved Pfizer's once-a-week injection for the two main types of a rare bleeding disorder called hemophilia, the company said on Friday.

Pfizer announced on Friday that the U.S. Food and Drug Administration has granted approval for its once-weekly injection designed to treat the two primary types of hemophilia, a rare

HYMPAVZI is the first and only approved anti-tissue factor pathway inhibitor in the US for haemophilia A or B treatment.

Today’s approval of Hympavzi provides patients with hemophilia a new treatment option that is the first of its kind to work by targeting a protein in the blood clotting process,” said Ann Farrell, M.D.